MARSEILLE, France–(BUSINESS WIRE)–#ANKET–Pursuant to the article L. 233-8 II of the French “Code de Commerce” and the article 223-16 of the French stock-market authorities (Autorité des Marchés Financiers, or “AMF”) General Regulation, Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) releases its total number of shares outstanding as well as its … [Read more…]
Updated results from phase 1 trial, including first presentation of data from a cohort of patients with EGFR-mutated metastatic non-small cell lung cancer, featured during a Presidential Session at JSMO Subgroup analysis by HER2 expression from phase 1/2 trial of patients with HER3 expressing metastatic breast cancer highlighted in a second Presidential Session TOKYO & … [Read more…]
Results presented at AAD 2023 demonstrated that investigational agent LEO 138559 met its primary endpoint of change in the Eczema Area and Severity Index (EASI) compared with placebo1 Efficacy analysis showed significant improvement versus placebo across a variety of endpoints including EASI-75, EASI-90, and EASI-100, in adult patients with moderate-to-severe atopic dermatitis1 These results are … [Read more…]
Californians with diabetes will have access to Civica’s low-cost insulins via the CalRx Biosimilar Insulin Initiative CalRx will work with Civica to provide the most commonly used short- and long-acting insulins at planned prices of no more than $30 a vial and $55 for a box of five pre-filled pens LEHI, Utah–(BUSINESS WIRE)–Civica Inc. (Civica, … [Read more…]
– Patients treated with povorcitinib experienced improvements in total body and facial repigmentation; investigational therapy was well tolerated – Results were featured as an oral presentation in a late-breaking abstract session at the 2023 American Academy of Dermatology (AAD) Annual Meeting WILMINGTON, Del.–(BUSINESS WIRE)–$INCY–Incyte (Nasdaq:INCY) today announced new data from a Phase 2b clinical trial … [Read more…]
Late-Breaking Abstract and Oral Presentation at American Academy of Dermatology Annual Meeting Stage 1 of ongoing 52-week China pivotal AD trial met primary and secondary endpoints No efficacy plateau at Week 16 SAN DIEGO & TAICANG, China & SUZHOU, China–(BUSINESS WIRE)–Connect Biopharma Holdings Limited (Nasdaq: CNTB) (Connect Biopharma or the Company), a global clinical-stage biopharmaceutical … [Read more…]
Results demonstrated that delgocitinib cream provided statistically significant improvements in primary and all key secondary endpoints, which included both clinician-assessed and patient-reported efficacy outcomes compared to cream vehicle.1 Delgocitinib cream showed a statistically significant treatment effect compared to cream vehicle as early as four weeks after initiation of treatment.1 BALLERUP, Denmark–(BUSINESS WIRE)–LEO Pharma A/S, a … [Read more…]
Extensive updates from broad and innovative portfolio also to be presented The 2023 American Academy of Dermatology (AAD) Annual Meeting will see the data premiere of the phase III OLYMPIA 2 trial, where nemolizumab monotherapy met all primary and key secondary endpoints and demonstrated significant improvements on itch, skin clearance and sleep disturbance in adult … [Read more…]
– Patients achieving a high level of facial repigmentation (≥F-VASI90) at Week 52 maintained durable response one year following withdrawal of treatment – Continued treatment with Opzelura for up to two years resulted in sustained facial repigmentation and further improvements in facial and total body repigmentation – Data featured as oral presentations in two late-breaking … [Read more…]
Results for TAK-279 (Formerly NDI-034858) Show a Significantly Greater Proportion of Patients Achieved Psoriasis Area and Severity Index (PASI) 75 at Doses ≥5mg at 12 Weeks1 At the Highest Dose of TAK-279, 46% of Patients Achieved PASI 90 and 33% Achieved PASI 100 at 12 Weeks, Indicating a Near-Total or Total Clearance of Skin Lesions1 … [Read more…]
